Latest Vancomycin Stories
GLASGOW, Scotland, January 12, 2015 /PRNewswire/ -- Highlights - In September 2014, MGB Biopharma secured GBP4M ($6.4M) from leading
Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received fast track designation for ABSSSI (acute bacterial skin and skin structure infections) LAUSANNE, Switzerland,
On October 8, the FDA announced that one lot of Vancomycin Hydrochloride for Injection, USP, by Hospira Inc., is recalled due to uncontrolled storage during transit.
A preliminary study has shown the potential of treating recurrent Clostridium difficile infection with oral administration of frozen encapsulated fecal material from unrelated donors, which resulted in an overall rate of resolution of diarrhea of 90 percent.
LAUSANNE, Switzerland, October 7, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that
Topical report “Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014” worked out by Global Markets Direct is now available at MarketPublishers.com.
Company Completes Enrollment in Phase 2 Clinical Trial AUSTIN, Texas, Oct.
Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome CAMBRIDGE, Mass., Sept.
Data demonstrate potent, broad spectrum activity against gram-positive and gram-negative bacteria, including resistant organisms that cause skin infections NEW YORK, Sept.
New University of British Columbia research found that receiving antibiotic treatments early in life can increase susceptibility to specific diseases later on.
Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...
Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...
- A volcanic mudflow.